Covered recipient · General Payments record
BRYAN A MEHLHAFF
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$151,451.53
147 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $95,882.00 | 50 |
| Consulting Fee | $31,936.50 | 15 |
| Travel and Lodging | $14,019.75 | 35 |
| Honoraria | $6,300.00 | 8 |
| Food and Beverage | $3,309.46 | 38 |
| Education | $3.82 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $55,134.42 | 60 |
| Merck Sharp & Dohme Corporation | $21,650.00 | 8 |
| Bayer HealthCare Pharmaceuticals Inc. | $16,143.61 | 17 |
| SN Holdings, LLC | $15,642.92 | 19 |
| Myovant Sciences Inc. | $12,332.95 | 10 |
| Janssen Biotech, Inc. | $10,775.23 | 16 |
| Astellas Pharma US Inc | $4,245.00 | 2 |
| Janssen Global Services, LLC | $3,282.50 | 2 |
| Amgen Inc. | $2,750.00 | 1 |
| Dendreon Pharmaceuticals LLC | $2,700.00 | 2 |
| Janssen Scientific Affairs, LLC | $2,020.00 | 2 |
| Exelixis Inc. | $1,980.00 | 1 |
| Teleflex LLC | $1,440.00 | 2 |
| E.R. Squibb & Sons, L.L.C. | $1,030.00 | 1 |
| UROGEN PHARMA, INC. | $304.08 | 2 |
| Foundation Medicine, Inc. | $17.00 | 1 |
| Travere Therapeutics, Inc. | $3.82 | 1 |
Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRYAN A MEHLHAFF
NPI 1518978204 · CMS profile ID 23759
Allopathic & Osteopathic Physicians / Urology
SPRINGFIELD, OR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1518978204?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRYAN A MEHLHAFF, NPI 1518978204, CMS profile ID 23759. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518978204?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). BRYAN A MEHLHAFF, NPI 1518978204, CMS profile ID 23759. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518978204?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- BRYAN A MEHLHAFF, NPI 1518978204, CMS profile ID 23759, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 147 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1518978204?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
147 matching records · $151,451.53 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 147.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $1,100.00 | 09/20/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788344061 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,850.00 | 09/13/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834334265 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,700.00 | 09/13/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834344743 | CMS |
| Merck Sharp & Dohme Corporation | $2,000.00 | 09/10/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848309579 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,030.00 | 09/07/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783579003 | CMS |
| Janssen Biotech, Inc. | $1,000.00 | 09/03/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788344059 | CMS |
| AstraZeneca Pharmaceuticals LP | $607.20 | 09/01/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834326255 | CMS |
| AstraZeneca Pharmaceuticals LP | $59.02 | 09/01/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834327387 | CMS |
| AstraZeneca Pharmaceuticals LP | $72.55 | 09/01/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834328579 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 09/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834329051 | CMS |
| AstraZeneca Pharmaceuticals LP | $950.00 | 08/30/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834350363 | CMS |
| Merck Sharp & Dohme Corporation | $1,750.00 | 08/23/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848565191 | CMS |
| SN Holdings, LLC | $1,000.00 | 08/21/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 799962481 | CMS |
| SN Holdings, LLC | $1,727.46 | 08/21/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 799962485 | CMS |
| SN Holdings, LLC | $269.89 | 08/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 799962490 | CMS |
| Janssen Global Services, LLC | $1,262.50 | 08/11/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787616793 | CMS |
| Myovant Sciences Inc. | $1,300.00 | 07/22/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834970619 | CMS |
| Astellas Pharma US Inc | $2,250.00 | 07/20/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821446807 | CMS |
| Foundation Medicine, Inc. | $17.00 | 07/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 799851933 | CMS |
| Janssen Biotech, Inc. | $1,000.00 | 07/16/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788344053 | CMS |
| Janssen Biotech, Inc. | $22.03 | 07/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788344081 | CMS |
| SN Holdings, LLC | $1,000.00 | 07/15/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 799962459 | CMS |
| SN Holdings, LLC | $2,352.13 | 07/15/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 799962465 | CMS |
| SN Holdings, LLC | $342.05 | 07/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 799962469 | CMS |
| SN Holdings, LLC | $500.00 | 07/15/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 799962473 | CMS |
| SN Holdings, LLC | $500.00 | 07/15/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 799962477 | CMS |
| AstraZeneca Pharmaceuticals LP | $2.90 | 07/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834330681 | CMS |
| Janssen Global Services, LLC | $2,020.00 | 07/01/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 787616785 | CMS |
| Janssen Biotech, Inc. | $500.00 | 06/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788344051 | CMS |
| Merck Sharp & Dohme Corporation | $2,750.00 | 06/23/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848549081 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,850.00 | 06/21/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834343525 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,850.00 | 06/13/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834323981 | CMS |
| AstraZeneca Pharmaceuticals LP | $950.00 | 06/07/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834341881 | CMS |
| Myovant Sciences Inc. | $1,300.00 | 06/07/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834970615 | CMS |
| AstraZeneca Pharmaceuticals LP | $300.00 | 06/02/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834334919 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,850.00 | 05/30/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834318520 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,700.00 | 05/30/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834332469 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,700.00 | 05/30/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834337179 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,400.00 | 05/30/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834341019 | CMS |
| AstraZeneca Pharmaceuticals LP | $950.00 | 05/30/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834342495 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,250.00 | 05/30/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834342695 | CMS |
| AstraZeneca Pharmaceuticals LP | $700.00 | 05/30/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834353041 | CMS |
| AstraZeneca Pharmaceuticals LP | $69.07 | 05/19/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834329027 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.63 | 05/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834345037 | CMS |
| AstraZeneca Pharmaceuticals LP | $59.06 | 05/19/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834345701 | CMS |
| AstraZeneca Pharmaceuticals LP | $951.32 | 05/19/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834347069 | CMS |
| AstraZeneca Pharmaceuticals LP | $370.60 | 05/19/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834351907 | CMS |
| AstraZeneca Pharmaceuticals LP | $178.99 | 05/19/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834353979 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.33 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834320149 | CMS |
| AstraZeneca Pharmaceuticals LP | $77.42 | 05/13/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834352691 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $31,257.89 | 2 |
| PY2025 | Principal investigator | $1,356,789.94 | 96 |
| PY2024 | Recipient | $5,080.00 | 3 |
| PY2024 | Principal investigator | $2,470,355.33 | 119 |
| PY2023 | Recipient | $990.00 | 3 |
| PY2023 | Principal investigator | $1,090,162.80 | 94 |
| PY2022 | Principal investigator | $1,298,739.75 | 203 |
| PY2021 | Recipient | $5,328.00 | 1 |
| PY2021 | Principal investigator | $518,848.87 | 147 |
| PY2020 | Principal investigator | $1,645,512.71 | 136 |
| PY2019 | Principal investigator | $1,013,859.51 | 118 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
98 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $37,491.28 | 12/31/2025 | Non-covered Recipient Entity Oregon Urology Institute | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232927255 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,556.00 | 12/19/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175434502 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,042.00 | 12/18/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175434495 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,186.00 | 12/15/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175434414 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 12/01/2025 | Non-covered Recipient Entity Oregon Urology Institute | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228726686 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 11/28/2025 | Non-covered Recipient Entity Oregon Urology Institute | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228725004 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,752.00 | 11/27/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175434427 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $17,228.25 | 11/15/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Phase II, Open-label, Multi-Center, Randomized Study Comparing the Combination of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) and Androgen Receptor Pathway Inhibitor (ARPI) vs. Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in First-line Treatment | No dispute reported | 06/30/2026 | 1190305705 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $26,476.01 | 11/14/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUE PC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892651 |
| Principal investigator 1 | MEDIVATION LLC. | $300.02 | 11/13/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739414 |
| Principal investigator 1 | MEDIVATION LLC. | $6,882.20 | 11/13/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228740657 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $452.25 | 11/12/2025 | Non-covered Recipient Entity Unio Specialty Care Cancer Center Of Excellence San Diego | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | No dispute reported | 06/30/2026 | 1225419733 |
| Principal investigator 1 | MEDIVATION LLC. | $1,015.30 | 11/06/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739439 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 11/06/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739805 |
| Principal investigator 1 | MEDIVATION LLC. | $1,261.00 | 11/06/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228741001 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,195.00 | 10/30/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175434490 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $354,066.01 | 10/27/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of Lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and Lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway In | No dispute reported | 06/30/2026 | 1190305703 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $81,929.62 | 10/27/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) | No dispute reported | 06/30/2026 | 1190305707 |
| Principal investigator 1 | MEDIVATION LLC. | $600.04 | 10/23/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228739356 |
| Principal investigator 1 | MEDIVATION LLC. | $6,882.20 | 10/23/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228747790 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 10/02/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228740383 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 10/02/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228748035 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,802.00 | 09/29/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175434431 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 09/10/2025 | Non-covered Recipient Entity Oregon Urology Institute | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228727399 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 09/09/2025 | Non-covered Recipient Entity Oregon Urology Institute | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228725002 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 09/04/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228743247 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 09/04/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755150 |
| Principal investigator 1 | Janssen Research & Development, LLC | $872.00 | 08/28/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175434420 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,042.00 | 08/18/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175434466 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,556.00 | 08/11/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175434472 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $42,473.27 | 08/08/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUE PC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892374 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $36,369.72 | 08/08/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUE PC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892378 |
| Principal investigator 1 | Janssen Research & Development, LLC | $872.00 | 07/28/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175434524 |
| Principal investigator 1 | MEDIVATION LLC. | $293.00 | 07/24/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | PROSPER A MULTINATIONAL PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228742171 |
| Principal investigator 1 | MEDIVATION LLC. | $293.00 | 07/24/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | PROSPER A MULTINATIONAL PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATIONRESISTANT PROSTATE CANCER | No dispute reported | 06/30/2026 | 1228743318 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 07/03/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228742998 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 07/03/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754293 |
| Principal investigator 1 | MEDIVATION LLC. | $150.01 | 07/03/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756263 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 07/03/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756389 |
| Principal investigator 1 | MEDIVATION LLC. | $5,391.10 | 07/03/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756416 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 07/03/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228756420 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,930.00 | 06/27/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175434460 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $1,011.00 | 06/25/2025 | Non-covered Recipient Entity Oregon Urology Institute | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232927253 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,739.00 | 06/13/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175434519 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 06/12/2025 | Non-covered Recipient Entity Oregon Urology Institute | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228751913 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 06/11/2025 | Non-covered Recipient Entity Oregon Urology Institute | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753833 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 06/11/2025 | Non-covered Recipient Entity Oregon Urology Institute | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754602 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,984.50 | 06/10/2025 | Non-covered Recipient Entity Unio Specialty Care Cancer Center Of Excellence San Diego | BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients | No dispute reported | 06/30/2026 | 1225402497 |
| Recipient | Dendreon Pharmaceuticals LLC | $29,902.77 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891409 |
| Recipient | Dendreon Pharmaceuticals LLC | $1,355.12 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891413 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $29,902.77 | 06/05/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUE PC | ProvONE | No dispute reported | 06/30/2026 | 1247891961 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $1,355.12 | 06/05/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUE PC | ProvONE | No dispute reported | 06/30/2026 | 1247891966 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $9,750.00 | 06/05/2025 | Non-covered Recipient Entity ARIZONA UROLOGY SPECIALISTS | ProvONE | No dispute reported | 06/30/2026 | 1247891970 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 06/05/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228778502 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 06/05/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228789893 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 06/05/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790373 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 06/05/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790603 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 06/05/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791328 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 06/05/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792350 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,042.00 | 05/29/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175434484 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 05/08/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790119 |
| Principal investigator 1 | MEDIVATION LLC. | $596.70 | 05/08/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790363 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 05/08/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790450 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 05/08/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790514 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 05/08/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790961 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 05/08/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792114 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 05/08/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792174 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 05/08/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793106 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 05/08/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228793167 |
| Principal investigator 1 | Janssen Research & Development, LLC | $872.00 | 05/01/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175434479 |
| Principal investigator 1 | MEDIVATION LLC. | $9,123.35 | 04/17/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790762 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29,217.00 | 04/11/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175434408 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 04/03/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228791922 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,372.00 | 03/31/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175434513 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 03/24/2025 | Non-covered Recipient Entity Oregon Urology Institute | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228753409 |
| Principal investigator 1 | PFIZER INC. | $46,206.12 | 03/23/2025 | Non-covered Recipient Entity Oregon Urology Institute | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228754214 |
| Principal investigator 1 | PFIZER INC. | $46,207.89 | 03/23/2025 | Non-covered Recipient Entity Oregon Urology Institute | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228755347 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 03/06/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774775 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 03/06/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774847 |
| Principal investigator 1 | MEDIVATION LLC. | $596.70 | 03/06/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228774997 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 03/06/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775210 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 03/06/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775247 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 03/06/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775523 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 03/06/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228775884 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 03/06/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228785265 |
| Principal investigator 1 | MEDIVATION LLC. | $273.00 | 03/06/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228785912 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,314.00 | 03/03/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175434505 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $36,029.56 | 02/20/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUE PC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891696 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $9,948.83 | 02/20/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUE PC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891701 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $42,408.31 | 02/20/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUE PC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891705 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $550.00 | 02/20/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUE PC | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891709 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 02/06/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228777591 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,042.00 | 02/03/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175434436 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,186.00 | 02/03/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175434448 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,739.00 | 01/27/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175434442 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,739.00 | 01/27/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175434454 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 01/02/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228776198 |
| Principal investigator 1 | MEDIVATION LLC. | $1,092.00 | 01/02/2025 | Non-covered Recipient Entity OREGON UROLOGY INSTITUTE PC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228786239 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2024 | Amount invested | $0.00 | 4 |
| PY2024 | Value of interest | $1,959,650.80 | 4 |
| PY2023 | Amount invested | $0.00 | 2 |
| PY2023 | Value of interest | $1,921,275.88 | 2 |
| PY2022 | Amount invested | $0.00 | 2 |
| PY2022 | Value of interest | $927,512.49 | 2 |
| PY2021 | Amount invested | $0.00 | 2 |
| PY2021 | Value of interest | $861,261.60 | 2 |
| PY2020 | Amount invested | $0.00 | 2 |
| PY2020 | Value of interest | $2,208,364.57 | 2 |
| PY2019 | Amount invested | $0.00 | 2 |
| PY2019 | Value of interest | $965,241.16 | 2 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
14 records · PY2019–2024
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2024 | SN Holdings, LLC | $0.00 | $4,803.01 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1124771575 |
| PY2024 | SN Holdings, LLC | $0.00 | $192.12 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1124771577 |
| PY2024 | SN Holdings, LLC | $0.00 | $1,879,476.58 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1124773323 |
| PY2024 | SN Holdings, LLC | $0.00 | $75,179.09 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1124773325 |
| PY2023 | SN Holdings, LLC | $0.00 | $1,847,380.65 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1032887379 |
| PY2023 | SN Holdings, LLC | $0.00 | $73,895.23 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1032887385 |
| PY2022 | SN Holdings, LLC | $0.00 | $891,838.93 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 941609369 |
| PY2022 | SN Holdings, LLC | $0.00 | $35,673.56 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 941609373 |
| PY2021 | SN Holdings, LLC | $0.00 | $828,136.15 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 820125203 |
| PY2021 | SN Holdings, LLC | $0.00 | $33,125.45 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 820125209 |
| PY2020 | UroGPO LLC | $0.00 | $2,123,427.47 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 737139403 |
| PY2020 | UroGPO LLC | $0.00 | $84,937.10 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 737139467 |
| PY2019 | UroGPO LLC | $0.00 | $928,116.48 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 690774981 |
| PY2019 | UroGPO LLC | $0.00 | $37,124.68 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 690775045 |